AN2 Therapeutics announces initiation of Phase 2 trial of epetraborole

AN2 Therapeutics (ANTX) announced the initiation of a Phase 2 investigator-initiated clinical trial evaluating the safety, efficacy, and pharmacokinetics of epetraborole, an orally administered inhibitor of leucyl-tRNA synthetase, for the treatment of pulmonary disease caused by Mycobacterium abscessus. The 84-patient, multicenter, randomized, double-blind study is being led by Dr. Kevin Winthrop at Oregon Health & Science University, in collaboration with other investigators across an estimated 10-15 sites in the U.S. Patient screening has been initiated, with topline data planned for late 2027. “Individuals living with M. abscessus lung disease face an incredibly difficult treatment journey, and today’s milestone reflects our commitment to changing that trajectory,” said Eric Easom, Co-founder, Chairman, President, and CEO of AN2 Therapeutics. “M. abscessus pulmonary infection is a serious condition with no FDA-approved therapies and limited treatment options. We believe epetraborole’s oral dosing and targeted novel mechanism provide a strong foundation as we work to deliver better, more accessible treatment solutions for patients who urgently need them.”